Novo Nordisk A/S (CPH:NOVO.B)
317.95
+2.30 (0.73%)
Jun 26, 2026, 4:59 PM CET
Novo Nordisk Employees
Novo Nordisk had 69,505 employees as of December 31, 2025. The number of employees decreased by 7,844 or -10.14% compared to the previous year.
Employees
69,505
Change (1Y)
-7,844
Growth (1Y)
-10.14%
Revenue / Employee
4.83M DKK
Profits / Employee
1.80M DKK
Market Cap
1,408.22B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 69,505 | -7,844 | -10.14% |
| Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
| Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
| Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
| Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genmab | 3,088 |
| Coloplast | 17,083 |
| Demant | 26,704 |
| ALK-Abelló | 2,759 |
| H. Lundbeck | 5,000 |
| Zealand Pharma | 544 |
| Ambu A/S | 5,200 |
| Bavarian Nordic | 1,861 |
Novo Nordisk News
- 38 minutes ago - Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet - CNBC
- 1 day ago - Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly? - The Motley Fool
- 1 day ago - Swiss pharma at risk of US trade investigation, industry body says - Reuters
- 1 day ago - GLP-1s linked to smell and taste impairment in diabetes patients - Reuters
- 1 day ago - Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage - CNBC
- 2 days ago - An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. - The Motley Fool
- 2 days ago - Novo Nordisk (NVO) Has an Obesity-and-Diabetes Platform Bigger Than a One-Drug Hype Cycle - AlphaStreet
- 2 days ago - Lexaria Bioscience ‘s human study GLP-1-H26-7 has begun dosing - TheFly